CAN
DNLI icon

Cetera Advisor Networks’s Denali Therapeutics DNLI Stock Holding History

Cetera Advisor Networks’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,373
Closed -$239K – 2630
2023
Q1 		$239K Buy
+10,373
New +$285K ﹤0.01% 2201

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Cetera Advisor Networks's DNLI Position: Q2 2023 in Review

Cetera Advisor Networks sold out of Denali Therapeutics (DNLI) in Q2 2023, closing a stake of 10,373 shares — an estimated $239K sold.

Cetera Advisor Networks first reported a position in DNLI in Q1 2023 and held it in 1 quarter. The position peaked at $239K in Q1 2023. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2023.

  • Cetera Advisor Networks reported no remaining Denali Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cetera Advisor Networks sold 10,373 Denali Therapeutics shares in Q2 2023, an estimated $239K.
  • Cetera Advisor Networks first reported a position in Denali Therapeutics in Q1 2023 and held it in 1 quarter.
  • Cetera Advisor Networks's Denali Therapeutics position peaked at $239K in Q1 2023.
  • 203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2023.

Based on Cetera Advisor Networks's 13F filing for Q2 2023, filed 10 Aug 2023.